{"url_path":"/sec/vvos/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-037173-index.html","accession_number":"0001493152-26-037173","cik":"0001716166","ticker":"VVOS","issuer_name":"Vivos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-037173-index.html","primary_entity_key":"0001716166","primary_entity_name":"Vivos Therapeutics, Inc."},"word_count":81,"has_tables":true,"body_markdown":"**Item\n9.01. Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n99.1\n \n[Press Release, dated August 5, 2026.](ex99-1.htm)\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n** **\n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n**VIVOS\nTHERAPEUTICS, INC.**\n****\n\n \n \n\nDated:\nAugust 11, 2026  \nBy:\n*/s/\nR. Kirk Huntsman*\n\n        \nName:\nR.\nKirk Huntsman\n\n        \nTitle:\nChief\nExecutive Officer"}